Malignant ascites and pleural effusion

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Pleural effusion and ascites arise when serosal production exceeds lymphatic removal. Direct malignant seeding creates a protein-rich exudate, but cancer can also cause portal hypertension, venous obstruction, hypoalbuminaemia, cardiac failure, pulmonary embolism or infection. The first task is therefore not simply to drain fluid; it is to decide whether the collection explains symptoms, whether diagnosis is secure and whether another reversible process is present.

Ultrasound confirms accessible fluid and shows septation. A first unilateral pleural effusion is sampled with cytology, protein, LDH, cell differential, culture and pH when infection is possible, interpreted with paired serum protein and LDH. Negative cytology does not exclude malignancy, especially mesothelioma and some squamous tumours. CT guides image-targeted core or thoracoscopy, which provides larger tissue for histology and molecular testing.

Diagnostic ascitic fluid includes cell count, culture, albumin, protein and cytology. The serum–ascites albumin gradient separates portal-hypertensive physiology from low-gradient peritoneal processes more reliably than the old transudate label. Cytology is most useful with peritoneal carcinomatosis and less sensitive when ascites arises from liver metastasis and portal pressure. A neutrophil-rich sample or peritonism needs infection and secondary-perforation assessment urgently.

Definitive management is guided by recurrence and mechanics. An indwelling pleural catheter provides ambulatory repeated drainage and works with trapped lung. Talc pleurodesis aims to obliterate the space but needs an expanding lung and usually an inpatient drain or thoracoscopy. Recurrent ascites can be managed with repeated taps or a tunnelled catheter. Diuretics work best when portal hypertension contributes; escalating them in low-gradient carcinomatosis often causes renal and sodium harm with little fluid benefit.

Key points

Malignant fluid is a clinical-pathological diagnosis: cancer can coexist with heart failure, cirrhosis, infection, pulmonary embolism, renal disease or treatment toxicity.
First-line imaging for a suspected pleural or abdominal collection is ultrasound because it confirms fluid, estimates distribution and makes aspiration safer.
All pleural procedures should use contemporaneous thoracic ultrasound by a trained operator; never rely on a historic skin mark after position changes.
A first unexplained pleural effusion usually needs ultrasound-guided diagnostic aspiration for protein, LDH, pH when infection is possible, glucose, cell count, culture and cytology.
Pleural fluid meeting Light’s criteria is exudative, but this does not prove malignancy; cytology sensitivity varies substantially by tumour type.
If cytology is negative and suspicion remains, contrast CT and image-guided or thoracoscopic pleural biopsy provide the reference tissue diagnosis rather than repeated low-yield fluid samples.
A first or atypical ascites presentation needs diagnostic paracentesis for cell count, culture, albumin, total protein and cytology, with additional tests guided by pancreatic, chylous or urinary suspicion.
A serum–ascites albumin gradient of at least 11 g/L supports portal-hypertensive physiology and predicts a better chance of response to spironolactone-based diuresis.
First-line relief of tense symptomatic malignant ascites is ultrasound-guided therapeutic paracentesis, stopping or slowing for pain, hypotension or physiological deterioration.
Routine albumin replacement after malignant-ascites drainage is not supported in the same way as cirrhotic large-volume paracentesis; individualise for mixed portal disease and circulatory risk.
For repeatedly recurrent malignant ascites, a tunnelled peritoneal catheter can allow smaller home drainage and reduce hospital procedures when patient and carers can manage it.
For recurrent symptomatic malignant pleural effusion with expandable lung, offer a choice of indwelling pleural catheter or talc pleurodesis based on admission, preference and treatment goals.
For non-expandable lung, an indwelling pleural catheter is usually preferred because pleurodesis requires visceral and parietal pleura to appose.
During one pleural aspiration, drain slowly and generally no more than 1.5 litres, stopping for chest tightness, pain, persistent cough, hypotension or worsening breathlessness.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Pleural or peritoneal tumour seeding

Breast, lung, ovarian, gastrointestinal and other cancers increase vascular permeability and obstruct lymphatic drainage by directly involving serosal surfaces.

Portal or venous hypertension

Massive liver metastases, portal-vein obstruction, cirrhosis, heart failure and venous thrombosis can create hydrostatic ascites alongside or instead of carcinomatosis.

Paramalignant fluid

Atelectasis, pneumonia, pulmonary embolism, hypoalbuminaemia, treatment cardiomyopathy and renal failure can cause effusion in a patient with cancer without malignant cells in fluid.

Lymphatic and chylous obstruction

Thoracic-duct, mediastinal or retroperitoneal tumour can produce triglyceride-rich chylous pleural fluid or ascites and substantial protein and lymphocyte loss.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Serosal permeability increases
Tumour and inflammatory mediators make pleural and peritoneal microvessels leaky, allowing protein-rich fluid to enter a space whose lymphatic clearance is impaired.
2
Fluid restricts organs
Pleural fluid compresses lung and diaphragm, while tense ascites elevates diaphragm, increases abdominal pressure and causes early satiety, reflux and reduced venous return.
3
Non-expandable lung limits pleurodesis
Visceral pleural tumour, fibrosis or endobronchial obstruction prevents lung apposition after drainage, leaving negative pressure pain and making chemical symphysis unlikely.
4
Protein and volume losses accumulate
Repeated external drainage removes protein, sodium and fluid, potentially worsening fatigue, oedema, hypotension and kidney function in a cachectic patient.
5
Tumour persistence drives recurrence
Aspiration removes fluid but not the malignant source, so recurrence interval and expected survival guide whether repeated taps or a definitive catheter strategy is preferable.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Pleural-effusion syndrome

Progressive breathlessness, dry cough, orthopnoea, reduced expansion and stony dullness suggest a moderate or large fluid collection but imaging confirms it.

Tense ascites syndrome

Increasing girth, early satiety, reflux, breathlessness, shifting dullness, oedema and umbilical or hernia discomfort indicate pressure and reduced abdominal capacity.

Pleural infectionRed flag

Fever, pleuritic pain, purulent fluid, loculation or low fluid pH with sepsis requires antibiotics and urgent drain pathway.

Non-expandable lung

Chest pain or cough during drainage, hydropneumothorax and persistent pleural space despite correct catheter position suggests visceral restriction or airway obstruction.

Portal-hypertensive ascites

Liver burden, splenomegaly, varices, oedema and a high serum–ascites albumin gradient support a hydrostatic component responsive to cautious diuresis.

Catheter complication

Redness, tunnel tenderness, cloudy output, leakage, loculated residual fluid or abrupt failure to drain needs prompt imaging, culture and pleural or peritoneal review.

Red flags requiring action

Marked respiratory distress, new oxygen need, hypotension or tracheal and mediastinal shift with a large pleural collection requires same-day specialist drainage assessment.
Fever, pleuritic pain, pus, pleural-fluid pH at or below the guideline drainage threshold or loculation suggests pleural infection requiring antibiotics and chest drainage.
Abdominal guarding, rebound, fever, lactate rise or free gas suggests perforation, ischaemia or secondary peritonitis rather than uncomplicated malignant ascites.
Sudden pleuritic pain, haemoptysis or disproportionate hypoxaemia can indicate pulmonary embolism even when a pleural effusion is visible.
Oliguria, hypotension, acute kidney injury or severe hyponatraemia after large-volume drainage requires circulatory, fluid and medicine reassessment.
A unilateral exudative effusion, pleural thickening or recurrent bloody fluid without secure pathology needs tissue diagnosis rather than repeated symptom-only aspiration.
New leakage, erythema, tunnel pain, cloudy fluid or failure to drain from an indwelling catheter requires prompt obstruction and infection evaluation.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
First-line pleural or abdominal ultrasoundFirst stepFirst line
Why
Confirm fluid, depth, septation, solid disease and a safe contemporary path for aspiration or catheter placement.
Interpretation and limitations
Identify diaphragm, liver, spleen and lung before pleural access and bowel and abdominal wall vessels before paracentesis; a tiny locule may need specialist imaging.
02
Pleural fluid diagnostic panel
Why
Measure protein, LDH, cell differential, pH and glucose when infection is possible, culture and cytology with paired serum values.
Interpretation and limitations
Light’s criteria identify an exudate but not its cause; prompt processing preserves pH accuracy and adequate cytology volume improves malignant-cell yield.
03
Reference pleural tissue diagnosis
Why
Obtain histology and molecular material by image-guided core or local-anaesthetic thoracoscopy when cytology is negative or insufficient.
Interpretation and limitations
Choose the thickened or nodular pleural target on contrast CT or ultrasound; repeated blind aspiration rarely resolves persistent tissue-level uncertainty.
04
Ascitic fluid diagnostic panel
Why
Measure cell count, culture, albumin, total protein and cytology, adding amylase, triglyceride or creatinine for a targeted leak question.
Interpretation and limitations
Calculate the gradient from a same-day serum albumin; at least 11 g/L supports portal hypertension, while malignant cytology confirms but negative cytology does not exclude cancer.
05
Contrast CT chest abdomen and pelvis
Why
Map pleural or peritoneal thickening, primary and metastatic tumour, venous obstruction, liver disease, bowel compromise and biopsy targets.
Interpretation and limitations
Fluid volume may obscure serosal implants and response after drainage can improve definition; CT morphology guides tissue but does not replace it when diagnosis matters.
06
Drainage-response assessment
Why
Measure symptoms, oxygen, blood pressure and ultrasound residual during or after therapeutic drainage to predict benefit and lung expandability.
Interpretation and limitations
Stop pleural aspiration for pressure symptoms or physiological deterioration; persistent pleural space after symptom-guided drainage supports non-expandable lung and changes definitive treatment.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Heart, liver or renal failure

Bilateral transudative pleural fluid, high-gradient ascites, oedema and organ-specific findings support hydrostatic disease that may respond to diuresis and cause treatment.

Pleural or peritoneal infection

Fever, pain, neutrophilic fluid, low pleural pH, positive culture or polymicrobial ascites requires antibiotics and drainage rather than cancer attribution.

Pulmonary embolism

Acute pleuritic pain, tachycardia and hypoxaemia can cause a small exudate and require probability-led thromboembolism testing despite known malignancy.

Pancreatic, urinary or chylous leak

High amylase, creatinine or triglyceride in fluid with compatible surgery, obstruction or trauma identifies a specific leak and changes intervention.

Tuberculosis and inflammatory serositis

Lymphocytic exudate, epidemiological risk, granulomatous pathology or autoimmune features can mimic malignant fluid and requires microbiology and tissue correlation.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01New pleural effusionSample safely, then secure tissue when neededFirst stepA new unilateral or otherwise unexplained pleural collection occurs in a patient with possible cancer.

1Assess respiratory stability, infection and thromboembolic features and obtain chest imaging and contemporaneous thoracic ultrasound before any needle procedure.
2Perform ultrasound-guided aspiration for biochemistry, culture and cytology and use contrast CT to map pleural, lung and nodal targets.
3If cytology is non-diagnostic and suspicion remains, obtain image-guided core or thoracoscopic biopsy with sufficient material for lineage and molecular testing.

02Recurrent pleural symptomsChoose catheter or pleurodesis by lung expansionA confirmed malignant pleural effusion recurs after helpful drainage.

1Reassess prognosis, treatment response, rate of recurrence, home support and whether the lung expands without substantial pain or residual space.
2Offer talc pleurodesis or an indwelling pleural catheter for expandable lung through shared decision; use the catheter preferentially when lung is non-expandable.
3Teach drainage limits and infection signs, monitor symptoms and imaging and manage loculation or blockage through the specialist pleural service rather than repeated emergency taps.

03New or tense ascitesDiagnose physiology and relieve pressureAbdominal fluid causes distension, satiety, pain, breathlessness or diagnostic uncertainty.

1Use ultrasound and diagnostic paracentesis to assess infection, albumin gradient, protein, cytology and selected leak markers while reviewing portal, cardiac, renal and venous causes.
2Drain symptomatic tense fluid under observation, monitoring blood pressure, pain and renal risk and avoiding automatic cirrhosis albumin rules when ascites is purely malignant.
3Treat the cancer and reversible mechanism and use spironolactone-based diuresis mainly when a high gradient or clinical portal hypertension makes response plausible.

04Rapidly recurrent ascitesMove from repeated taps to planned home controlBeneficial paracentesis is needed frequently and the patient prefers fewer hospital procedures.

1Confirm that symptoms improve with drainage, exclude untreated infection or loculated obstruction and discuss prognosis, leakage, protein loss and caregiver capacity.
2Insert a tunnelled peritoneal catheter through the specialist image-guided service and establish small-volume, symptom-led home drainage with supplies and nursing support.
3Monitor wound, tunnel, output, renal function and infection and review whether continuing drainage remains beneficial as intake, pressure and end-of-life goals change.

Key medicines and prescribing safety3 treatments · regimens, roles and cautions

Promotes sodium and water loss in high-gradient or mixed portal malignant ascites; low-gradient peritoneal carcinomatosis often responds poorly.

Spironolactone-based diuresis for selected ascites

When portal-hypertensive physiology is likely, start spironolactone commonly at 100 mg orally each morning, adding furosemide 40 mg daily if needed and titrating cautiously to weight, symptoms, renal function and electrolytes.

Monitor potassium, sodium, creatinine, pressure and daily weight; stop or reduce for hypotension, renal injury, severe sodium change or potassium disturbance and review interacting renin–angiotensin medicines.

Produces pleural symphysis to reduce recurrent malignant-effusion accumulation in a patient with expandable lung.

Sterile graded talc pleurodesis

Give 4 g sterile graded talc as slurry through a correctly positioned chest drain or by thoracoscopy under the specialist pleural protocol after confirming adequate lung apposition.

Provide analgesia, discuss fever and pain and avoid ungraded talc; pleurodesis is unlikely to succeed with substantial non-expandable lung or uncontrolled pleural infection.

Treats empyema, catheter infection or peritonitis that may coexist with malignant fluid and requires drainage rather than anti-cancer attribution.

Antibiotics for infected malignant fluid

Start the local severe pleural or intra-abdominal infection intravenous regimen immediately after cultures when feasible, then tailor spectrum, route and duration to source control, microbiology, renal function and response.

Do not wait for cytology or final culture in sepsis; check allergy, recent resistance and organ function and remove or preserve an indwelling catheter according to infection depth and specialist advice.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Respiratory and functional decline

Pleural and abdominal fluid restricts diaphragmatic excursion, causing breathlessness, orthopnoea, poor sleep, reduced mobility and inability to tolerate cancer treatment.

Infection and catheter sepsis

Repeated needles and long-term drains can cause cellulitis, tunnel infection, empyema or peritonitis, sometimes requiring antibiotics, fibrinolysis or catheter removal.

Re-expansion and pressure injury

Rapid pleural drainage can cause chest pain, cough, hypotension and rare re-expansion pulmonary oedema, while non-expandable lung causes persistent pneumothorax ex vacuo.

Renal and circulatory dysfunction

Large or frequent ascitic drainage can reduce effective circulation, worsen sodium and kidney function and complicate diuretic and systemic-treatment delivery.

Loculation and drain failure

Fibrin, tumour and infection divide the space, making a single catheter drain poorly and requiring ultrasound, saline, fibrinolytic or alternative intervention review.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

During pleural aspiration, monitor symptoms, respiratory rate, oxygen and blood pressure and stop for chest tightness, pain, persistent cough or physiological deterioration.
After any drainage, record amount, appearance, specimen destination, symptom response and residual fluid and ensure every cytology, culture and histology result has an owner.
For indwelling pleural catheter, track breathlessness, drainage volume and frequency, lung expansion, wound, tunnel, leakage, blockage and cloudy or malodorous fluid.
For recurrent ascites, monitor girth or pressure symptoms, weight, intake, oedema, pressure, sodium, potassium and renal function without chasing complete dryness.
During diuresis, use daily weight and orthostatic symptoms and repeat chemistry within the local titration interval; stop ineffective treatment before renal harm accumulates.
For a tunnelled peritoneal catheter, use symptom-led smaller drainage, inspect site and train patient and carers on sterile technique and urgent infection signs.
Reassess whether drainage still improves breathing, eating, sleep and mobility as cancer progresses, avoiding automatic procedures that no longer meet the patient’s goals.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

Cancer does not make every effusion malignant

Heart failure, embolism, infection and hypoalbuminaemia may be more treatable and can coexist with positive cancer history or even positive cytology.

Light’s criteria classify, not diagnose

An exudate narrows physiology but does not distinguish malignant, infectious, embolic, inflammatory and several treatment-related causes.

Pleurodesis needs pleural apposition

When visceral tumour prevents lung expansion, chemical irritation cannot bring surfaces together and an indwelling catheter is mechanically more rational.

The albumin gradient predicts mechanism

A high gradient indicates portal pressure and a more plausible diuretic response, even when metastatic cancer is the underlying reason.

Symptom response matters more than litres

Drainage should stop when benefit is reached or pressure symptoms appear; a numerical target can cause unnecessary haemodynamic and pleural injury.

Home drainage changes the burden, not biology

A tunnelled catheter reduces repeated hospital procedures but still requires infection, supply, caregiver and end-of-life planning.

11Common pitfallsFrequent interpretation and management errors.

01
Assuming all fluid in a patient with cancer contains malignant cells.
02
Performing pleural aspiration without contemporaneous ultrasound and trained anatomical identification.
03
Calling an exudate malignant from Light’s criteria alone.
04
Repeating pleural cytology indefinitely instead of obtaining tissue after persistent negative results.
05
Draining pleural fluid rapidly to a fixed maximum despite pain, cough or hypotension.
06
Attempting talc pleurodesis in substantial non-expandable lung.
07
Applying cirrhotic albumin replacement automatically to every malignant-ascites drainage.
08
Escalating spironolactone in low-gradient ascites despite renal and sodium harm.
09
Placing a tunnelled catheter without a home-care, supplies and infection plan.
10
Continuing drainage when it no longer improves any patient-valued symptom.